Studies for Men with HIV

• Anti-Lipolytic Strategy for HIV Lipodystrophy
  The study will evaluate the use of acipimox, a drug that blocks the breakdown of fat and is used to treat high cholesterol. People with HIV lipodystrophy (fat redistribution) may have high blood levels of cholesterol and triglyceride (small particles of fat in the blood). We are evaluating whether acipimox will reduce triglyceride levels in individuals with HIV lipodystrophy.

For more information, please contact Jim Liebau, NP at (617) 724-6926.

• Effects of a Lifestyle Modification Program (REACH) in Patients with HIV and Metabolic Syndrome
  This study will determine the effects of an intensive lifestyle modification program, focusing on healthy eating and exercise, in patients with HIV and Metabolic Syndrome. Metabolic Syndrome is a cluster of characteristics such as high blood pressure, high cholesterol, large waist circumference, and insulin resistance. We hope to improve body composition, blood pressure, cholesterol levels, and other factors including quality of life. Patients will be randomly selected for one-on-one sessions with a nutritionist over six months.

For more information, please contact Kathleen Fitch, NP at (617) 724-8015.

• FDG/PET Imaging for the Evaluation of Glucose Metabolism in HIV
  In this research study, our aim is to determine whether HIV-infected patients with arm/leg fat loss have decreased sugar metabolism in the fat tissues of the legs and abdomen. Techniques will include CT, MRI, and dynamic positron emision tomography (PET) imaging. Eligible subjects will be evaluated on two separate visits.

For more information, please contact Dr. Daniel Kamin at (617) 724-3572.

• Long-term Physiologic Effects of GH in HIV Lipodystrophy
  HIV positive subjects age 18-65 with changes in body fat distribution are needed for a three-year research study investigating treatment with growth hormone. Participants will self-inject growth hormone for 18 months and placebo (contains no active ingredients) for 18 months. Participation in this study requires an initial screen visit, and, if you qualify, 17 outpatient visits over 3 years. Compensation up to $500 is provided.

For more information, please contact Dr. Polyxeni Koutkia at (617) 726-8277.